Anticoagulant News and Research

RSS
Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Educational program does not influence patients’ adherence to apixaban anticoagulant

Educational program does not influence patients’ adherence to apixaban anticoagulant

ESC guideline adherent antithrombotic management improves outcomes in AF patients

ESC guideline adherent antithrombotic management improves outcomes in AF patients

GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Cryptogenic stroke frequent and recurrent

Cryptogenic stroke frequent and recurrent

Scientists develop artificial blood vessels that are resistant to blood clot formation

Scientists develop artificial blood vessels that are resistant to blood clot formation

More people turn to popular new blood thinners for atrial fibrillation treatment

More people turn to popular new blood thinners for atrial fibrillation treatment

Use of dicloxacillin linked to INR decrease in patients taking vitamin K antagonists

Use of dicloxacillin linked to INR decrease in patients taking vitamin K antagonists

New UTMB study finds no association between testosterone therapy and blood clots in veins

New UTMB study finds no association between testosterone therapy and blood clots in veins

Alternative approach to treat fatal blood clots found to be more effective in patients

Alternative approach to treat fatal blood clots found to be more effective in patients

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

DGIST researchers set on creating microrobot-assisted procedure for dealing with blocked arteries

DGIST researchers set on creating microrobot-assisted procedure for dealing with blocked arteries

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.